scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1080/07357900500449694 |
P698 | PubMed publication ID | 16466993 |
P50 | author | Heinz-Josef Lenz | Q89668545 |
P2093 | author name string | Anthony B El-Khoueiry | |
P2860 | cites work | Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue | Q27863454 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study | Q28189472 | ||
Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy | Q30433652 | ||
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer | Q33978749 | ||
Optimal use of the combination of irinotecan and 5-fluorouracil | Q35152551 | ||
5-Fluorouracil by Protracted Venous Infusion: A Review of Recent Clinical Studies | Q36810361 | ||
5-Fluorouracil by protracted venous infusion. A review of current progress | Q38653866 | ||
A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma | Q43819026 | ||
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gas | Q44578293 | ||
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis | Q45057200 | ||
The incorporation of 5-fluoro-2'-deoxyuridine into DNA of mammalian tumor cells. | Q52162964 | ||
Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. | Q54510265 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | fluorouracil | Q238512 |
P304 | page(s) | 50-55 | |
P577 | publication date | 2006-02-01 | |
P1433 | published in | Cancer Investigation | Q325953 |
P1476 | title | Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? | |
P478 | volume | 24 |
Q64273134 | Cisplatin, Fluorouracil in Bolus Injection, and Leucovorin in First-Line Therapy for Advanced Gastric Cancer as an Alternative to Protocols With Infusional Fluorouracil |
Q38938577 | Formulation and pharmacokinetics of thermosensitive stealth® liposomes encapsulating 5-Fluorouracil. |
Q39996690 | Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors |
Q46844116 | In-vitro and in-vivo studies of pectin/ethylcellulosefilm-coated pellets of 5-fluorouracil for colonic targeting |
Q33866280 | Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil |
Q36840074 | Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies |
Q33788372 | N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU. |
Q39566084 | Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. |
Q36634272 | The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. |
Search more.